Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug

J Natl Cancer Inst. 2011 Feb 2;103(3):170-1, 177. doi: 10.1093/jnci/djr016. Epub 2011 Jan 17.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm*
  • Gene Expression Regulation, Enzymologic
  • Gene Expression Regulation, Neoplastic
  • Genes, ras / drug effects
  • Humans
  • Indoles / pharmacology*
  • MAP Kinase Kinase Kinases / metabolism
  • Melanoma / drug therapy*
  • Melanoma / secondary
  • Mutation*
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism*
  • Proto-Oncogene Proteins c-raf / metabolism
  • Receptors, Platelet-Derived Growth Factor / metabolism
  • Signal Transduction / drug effects
  • Sulfonamides / pharmacology*
  • Time Factors
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Indoles
  • Proto-Oncogene Proteins
  • Sulfonamides
  • Vemurafenib
  • Receptors, Platelet-Derived Growth Factor
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins c-raf
  • MAP Kinase Kinase Kinases
  • MAP3K8 protein, human